NCT02006004

Brief Summary

Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary AML in the PETHEMA Group institutions. This study is a non-interventional research regarding diagnosis and therapeutic approach

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

November 26, 2013

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 9, 2013

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

October 14, 2015

Status Verified

October 1, 2015

Enrollment Period

3.3 years

First QC Date

November 26, 2013

Last Update Submit

October 13, 2015

Conditions

AML

Keywords

AML

Outcome Measures

Primary Outcomes (1)

  • Characteristics of the patients diagnosed with AML

    To realize an epidemiologic and retrospective study to assess the characteristics of the patients diagnosed with AML and their disease, regardless the age or treatment

    3 years

Secondary Outcomes (2)

  • Prognosis factors

    3 years

  • Risk factors

    3 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with acute myeloid leukemia

You may qualify if:

  • Patients diagnosed with acute myeloid leukemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital La Fe

Valencia, Valencia, Spain

Location

Study Officials

  • Sanz Miguel Angel, DR

    Hospital La Fe

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 26, 2013

First Posted

December 9, 2013

Study Start

January 1, 2012

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

October 14, 2015

Record last verified: 2015-10

Locations

ES(1)